Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial
Background: Studies differ regarding whether, compared with courses of conventional duration, longer-term antithyroid drug treatment increases frequency of remission in patients with Graves' hyperthyroidism. We prospectively conducted a randomized, parallel-group study comparing relapse rates i...
Gespeichert in:
Veröffentlicht in: | Thyroid (New York, N.Y.) N.Y.), 2019-09, Vol.29 (9), p.1192-1200 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background:
Studies differ regarding whether, compared with courses of conventional duration, longer-term antithyroid drug treatment increases frequency of remission in patients with Graves' hyperthyroidism. We prospectively conducted a randomized, parallel-group study comparing relapse rates in patients receiving longer-term versus conventional-length methimazole therapy. We also sought variables associated with relapse following the latter.
Methods:
We enrolled 302 consecutive patients with untreated first episodes of Graves' hyperthyroidism. After 18–24 months of methimazole, 258 patients (85.4%) were randomized to an additional 36–102-month courses (“long-term group”:
n
= 130; scheduled total time on methimazole: 60–120 months) or discontinuation of methimazole (“conventional group”:
n
= 128). Patients were followed 48 months postmethimazole cessation. We performed Cox proportional hazards modeling to identify factors associated with relapse after conventional courses.
Results:
Methimazole was given for 95 ± 22 months in long-term patients and 19 ± 3 months in the conventional group. Fourteen patients experienced cutaneous reactions and 2 liver enzyme elevations during the first 18 months of treatment; no further methimazole-related reactions were observed despite therapy for up to another 118 months. Hyperthyroidism recurred within 48 months postmethimazole withdrawal in 15% (18/119) of long-term patients versus 53% (65/123) of conventional group patients. In the conventional group, older age, higher triiodothyronine or thyrotropin receptor antibody concentrations, lower thyrotropin concentration, or possession of the rs1879877
CD28
polymorphism or the
DQB1-05 HLA
polymorphism were independently associated with relapse.
C
onclusion:
Administration of low-dose methimazole for a total of 60–120 months safely and effectively treats Graves' hyperthyroidism, with much higher remission rates than those attained by using conventional 18–24-month courses. |
---|---|
ISSN: | 1050-7256 1557-9077 |
DOI: | 10.1089/thy.2019.0180 |